These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9367671)

  • 41. Jacobsen catalyst as a cytochrome P450 biomimetic model for the metabolism of monensin A.
    Rocha BA; de Oliveira AR; Pazin M; Dorta DJ; Rodrigues AP; Berretta AA; Peti AP; de Moraes LA; Lopes NP; Pospíšil S; Gates PJ; Assis Md
    Biomed Res Int; 2014; 2014():152102. PubMed ID: 24987668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monensin mediates a rapid and selective transport of Pb(2+). Possible application of monensin for the treatment of Pb(2+) intoxication.
    Hamidinia SA; Shimelis OI; Tan B; Erdahl WL; Chapman CJ; Renkes GD; Taylor RW; Pfeiffer DR
    J Biol Chem; 2002 Oct; 277(41):38111-20. PubMed ID: 12080080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Laidlomycin phenylcarbamate, a semisynthetic polyether antibiotic.
    Clark RD; Maddox ML; Spires HR; Long PL
    J Antibiot (Tokyo); 1986 Dec; 39(12):1765-8. PubMed ID: 3818449
    [No Abstract]   [Full Text] [Related]  

  • 44. Intermediates in monensin biosynthesis: A late step in biosynthesis of the polyether ionophore monensin is crucial for the integrity of cation binding.
    Hüttel W; Spencer JB; Leadlay PF
    Beilstein J Org Chem; 2014; 10():361-8. PubMed ID: 24605157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ionophore Toxicity in Animals: A Review of Clinical and Molecular Aspects.
    Ekinci İB; Chłodowska A; Olejnik M
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
    Nebbia C; Ceppa L; Dacasto M; Carletti M; Nachtmann C
    Drug Metab Dispos; 1999 Sep; 27(9):1039-44. PubMed ID: 10460804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oxidative monensin metabolism and cytochrome P450 3A content and functions in liver microsomes from horses, pigs, broiler chicks, cattle and rats.
    Nebbia C; Ceppa L; Dacasto M; Nachtmann C; Carletti M
    J Vet Pharmacol Ther; 2001 Dec; 24(6):399-403. PubMed ID: 11903870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biochemical background of toxic interaction between tiamulin and monensin.
    Szucs G; Tamási V; Laczay P; Monostory K
    Chem Biol Interact; 2004 Mar; 147(2):151-61. PubMed ID: 15013817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A selective decrease in cytochrome P450 in the liver microsomes of male rats following phenobarbital and 3-methylcholanthrene induction and acute tetrachloromethane poisoning].
    Angelov EP
    Eksp Med Morfol; 1993; 31(3-4):1-15. PubMed ID: 7805614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure and antimicrobial properties of monensin A and its derivatives: summary of the achievements.
    Aowicki D; Huczyński A
    Biomed Res Int; 2013; 2013():742149. PubMed ID: 23509771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 'In vitro' interactions of monensin with hepatic xenobiotic metabolizing enzymes.
    Ceppa L; Dacasto M; Carletti M; Montesissa C; Nebbia C
    Pharmacol Res; 1997 Sep; 36(3):249-54. PubMed ID: 9367671
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.